Salih, Noralin J.
HRN: 22-47-82 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/13/2023
CO-AMOXICLAV 625MG (TAB)
01/13/2023
01/19/2023
PO
625mg
BID
2nd Degree RMLE
Waiting Final Action
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes